09
Aug
Mumbai (Maharashtra) [India], August 9: Cupid Limited (BSE – 530843, NSE – CUPID) is rapidly scaling its In-Vitro Diagnostic (IVD) test kits business, driven by strong domestic demand, a growing international footprint and a clear expansion strategy. Key Highlights: • Diverse Product Portfolio: 15 IVD rapid test kits currently in production, including HIV, Syphilis, Pregnancy, and Hepatitis B; 3 new kits under development. • Regulatory Certifications in Progress: o CE Certification for 4 key products expected soon in 2025. o WHO Prequalification for Malaria Test Kit targeted by mid-2026. o Application for Malaria Pf Ag WHO prequalification by Q3 2026.…
